HTHideshi Tsusaki

Hideshi Tsusaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hideshi Tsusaki has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Hideaki Hara

    Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University

    2 shared publications
  • Kodai Ishida

    Dept. Biomed. Res. Lab., Gifu Pharm. Univ

    2 shared publications
  • Shinsuke Nakamura

    Mol. Pharmacol., Dept. Biofunc. Eval., Gifu Pharm. Univ

    2 shared publications
  • Hiroshi Yamazaki

    Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan

    1 shared publication
  • Masamitsu Shimazawa

    Department of Biomedical Research Laboratory, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan; Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan

    1 shared publication
  • Masamitsu Shimazawa

    Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan

    1 shared publication

Latest Publications

  • Open Access

    Protective effect of N-acetylcysteine against the cytoskeletal injury induced by cigarette tobacco extract and heated tobacco products in C2C12 myoblasts

    by Otsu Wataru, Naoki Chinen, Kodai Ishida, Shinsuke Nakamura, Masamitsu Shimazawa, Hideshi Tsusaki, Hideaki Hara

    Sarcopenia is an age-related skeletal muscle disorder characterized by the progressive loss of muscle mass and function, resulting in physical disability and mortality. Aberrant reactive oxygen species (ROS) generation and oxidative tissue damages in skeletal muscles have been implicated as one of key causative factors in the multiple mechanisms of sarcopenia. Tobacco smoke contains many toxic chemicals including highly unstable free radicals and ROS. Currently, heated tobacco products (HTPs) are widely used as substitutes for cigarette smoking around the world. However, it is poorly understood the effects of these new generation tobacco products on skeletal muscles. In the present study, we investigated the muscular injury induced by cigarette smoke extract (CSE) and HTPs using murine myoblast C2C12 cells as an in-vitro model. The exposure of either CSE or HTPs for 24 h decreased the cell viability in C2C12 myoblasts, which protected by treatment with 1 mM N-acetylcysteine (NAC). In addition, the differentiation to myotube and the expression of myogenic marker protein were suppressed by CSE or HTPs exposure. Interestingly, the formation of stress fibers was disrupted by the treatment with CSE, and the aberrant membrane protrusion was observed. These abnormalities in cytoskeletons and cell shapes were also rescued by the treatment of NAC. These findings suggested that CSE and/or HTPs can damage skeletal muscles through the impairment of cytoskeleton formation, which may contribute to the progress of muscular damages, and age-related muscular diseases.

  • Genetic variants of UDP-glucuronosyltransferases 1A1, 1A6, and 1A9 in cynomolgus and rhesus macaques

    by Yasuhiro Uno, Takahiro Mikami, Yasuko Tsukazaki, Yasuharu Nakanishi, Norie Murayama, Shinichi Ikushiro, Hideshi Tsusaki, Hiroshi Yamazaki

    1. In the cynomolgus macaque, UDP-glucuronosyltransferases (UGTs) 1As have similar molecular and enzymatic characteristics to those of their human orthologs. However, genetic polymorphisms in major cynomolgus UGT1A1/6/9 have not been investigated. 2. We re-sequenced UGT1A1, UGT1A6, and UGT1A9 in 186 cynomolgus macaques (bred in Cambodia, China, or Indonesia) and 54 rhesus macaques and found 15, 13, and 26 non-synonymous variants, respectively. 3. Of these UGT1A1, UGT1A6, and UGT1A9 variants, respectively, 10, 9, and 12 were unique to cynomolgus macaques; 4, 1, and 2 were unique to rhesus macaques; and 1, 2, and 5 were found in both cynomolgus and rhesus macaques. The frequency of the UGT1A1 mutation G69R was 23%, 28%, and 63% in cynomolgus macaques bred in Cambodia, China, and Indonesia, respectively, and 97% in rhesus macaques. 4. The O-glucuronidation activities of liver microsomes from cynomolgus and rhesus macaques with respect to estradiol, serotonin, and propofol were measured. Among these activities, liver microsomes from cynomolgus macaques heterozygous for UGT1A1 G69R (n = 11) showed significantly reduced estradiol 3-O-glucuronidation activities compared with those from wild-type animals (n = 38). 5. These results suggest genetic variants such as UGT1A1 G69R could influence the UGT1A1-mediated glucuronidation of drugs in cynomolgus and rhesus macaques.